Pharmaceutical

Cold agglutinin disease by NovelMed Therapeutics for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval

Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.

Jul 1, 2023 - 20:00
Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia.
Read the original article

Tags:

Previous Article

Immune Thrombocytopenia by NovelMed Therapeutics for Idiopathic Thrombocytopenic...

Next Article

XKDCT-080 by Guangdong Xiankangda Biotechnology for Colorectal Cancer: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: FDA panel backs conditional approval for Biogen ALS drug; pharma fights tactic for lowering specialty med costs

STAT+: Pharmalittle: FDA panel backs conditional approv...

Mar 24, 2023

Final report says UK infected blood scandal “should have been avoided”  

Final report says UK infected blood scandal “should hav...

May 21, 2024

EC approves Celltrion’s Omlyclo for allergic conditions

EC approves Celltrion’s Omlyclo for allergic conditions

May 25, 2024